Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.

Optimizing COVID-19 Booster Shot Usage: A New Sheba Study

COVID-19 Booster Shot study at Sheba Medical Center in Israel.
With a new indication regarding the efficacy period of the fourth COVID-19 shots, it is clear that their administration, and that of future boosters, must be timed properly

A new Sheba study involving first-generation Pfizer COVID-19 vaccines, published in the New England Journal of Medicine, showed that the fourth vaccine dose increased antibody levels for only around 13 weeks. 

Conducted by Sheba researchers alongside experts from the Israeli Health Ministry and Columbia University researchers, the study comprised over 6,000 Sheba employees and volunteers.

Based on the findings, Sheba researchers suggest healthcare providers should plan booster shot administration carefully, as added protection against infection peaks for a relatively short period, i.e., boosters should be given when episodes of high infection are expected or when specific patients face circumstances that make them more prone to infection and serious disease. 

According to Prof. Regev-Yochay, Director of the Infectious Prevention and Control Unit at Sheba and one of the study’s lead authors, it is necessary to “take into consideration not only surges in infection, but also personal medical conditions, upcoming events, travel plans, and high risk periods.”

While it remains unclear how antibody levels correlate with protection against serious illness, the study did not examine the possibility that the vaccine may offer protection against severe forms of the disease for longer than three months, the period in which antibody levels are high.

Sheba Leverages ChatGPT
Accelerating Diagnostics: ChatGPT Results Aligned with Breast Cancer Board Recommendations
Recently, several distinguished Sheba clinicians were impressed by the tool’s capabilities. The group, which included Dr. Vera Sorin, Dr. Eyal Klang, Dr. Miri Sklair-Levy, Prof.…
Read More
Sheba and Vidac
Novel Drug Set to Improve CAR T-Cell Therapy Effectiveness
While many medical centers around the world depend on external labs to genetically engineer patient T-cells, a process that can take up to a few…
Read More
Sheba Named Global Oncology Leader
by Newsweek Magazine
Dedicated to providing those in need across the globe ‘Hope Without Boundaries,’ Sheba treats patients from more than 100 countries each year, employing the latest…
Read More